The Safety and Efficacy of the Suture-Mediated Closure System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

228 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-26

Study Completion Date

2023-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a prospective, multicenter, randomized, controlled, non-inferiority clinical study with the primary objective of validating the safety and efficacy of the Suture-Mediated Closure System for percutaneous closure of the common femoral artery puncture site.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Characteristics Predictive of Success and Complications in the Use of Suture-Mediated Closure of Femoral Venous Access

NCT00838175

Cardiac Catheterization

UNKNOWN

Study to Evaluate Safety & Effectiveness of Vascular Sealant System

NCT00439309

Peripheral Vascular Disease

TERMINATED NA

Vascular Sealant Study

NCT00618358

Arteriovenous Access Grafts or Extra-anatomic and Infra-inguinal Grafts

TERMINATED PHASE1

Feasibility and Safety of Total Percutaneous Closure of Femoral Arterial Access Sites in the Veno-arterial ECMO Patients

NCT04689451

Cardiogenic Shock Extracorporeal Membrane Oxygenation Myocarditis +4 more

UNKNOWN

Time to Ambulation After ProGlide Closure

NCT07179536

Femoral Access Site Closure Ambulation Vascular Access Complication +1 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was a prospective, multicenter, randomized, controlled, non-inferiority clinical trial. It is planned to be conducted in multiple clinical trial institutions and enroll 228 subjects. Eligible subjects were randomly divided into the experimental group or the control group at a ratio of 1:1.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease Arterial Puncture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

the Suture-Mediated Closure System

Produced by Zhejiang Zylox Medical Device Co., Ltd.

Group Type EXPERIMENTAL

the Suture-Mediated Closure System

Intervention Type DEVICE

To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site

Perclose ProGlide Suture-Mediated Closure System

Perclose® ProGlide Suture-Mediated Closure System

Group Type ACTIVE_COMPARATOR

Perclose ProGlide Suture-Mediated Closure System

Intervention Type DEVICE

To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

the Suture-Mediated Closure System

To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site

Intervention Type DEVICE

Perclose ProGlide Suture-Mediated Closure System

To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between 18 years old and 85 years old, randomized
* Patients who can be examined or treated with a common femoral artery puncture interventional catheter using a 5F to 22F sheath tube
* Patient(or their guardians) who submitted a written informed consent for the this trial

Exclusion Criteria

* Known to be pregnant or lactating
* The diameter of femoral artery on the puncture side was less than 5mm
* Patients requiring anterograde puncture approach
* Have participated in or plan to participate in another clinical trial in the same period
* Known allergy to any components of the device, and/or contraindications to contrast agents and anticoagulants
* International normalized ratio (INR) \>2.0
* Traumatic vascular injury at the approach site
* Systemic or local groin infection
* Cerebrovascular accident or myocardial infarction within 3 months
* An arterial catheter needs to be placed at the access site
* Morbidly obese (BMI ≥40 kg/m2)
* The entire common femoral artery wall assessed by ultrasound, calcification located in the anterior wall cut, the extent of more than 50% circumferential or common femoral artery stenosis ≥50
* Femoral artery aneurysm, arteriovenous fistula or pseudoaneurysm in common femoral artery
* Using a clip vessel occluder at the past ipsilateral femoral artery access site
* Use of a puncture point occlusion device at the ipsilateral femoral access site within the past 30 days
* Underwent an intervention via ipsilateral femoral artery puncture within the past 30 days or within the next 30 days
* Ipsilateral femoral vein sheath needed to be used
* Evidence of previous common femoral artery surgery on the same side (e.g., inguinal incision)
* Hematoma at ipsilateral arterial access
* Other circumstances that the investigator deemed inappropriate for participation in the trial.femoral artery aneurysm, arteriovenous fistula or pseudoaneurysm in common femoral artery

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No